Adding Radioligand to Enzalutamide Boosts OS in Metastatic CRPC

(MedPage Today) -- SAN FRANCISCO -- The addition of radionuclide therapy with 177Lu-PSMA-617 (Pluvicto) to enzalutamide (Xtandi) improved overall survival (OS) in patients with metastatic castration-resistant prostate cancer (CRPC), according...